Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized, Double-blind, Evaluation in Secondary Stroke Prevention Comparing the EfficaCy and Safety of the Oral Thrombin Inhibitor Dabigatran Etexilate (110 mg or 150 mg, Oral b.i.d.) Versus Acetylsalicylic Acid (100 mg Oral q.d.) in Patients With Embolic Stroke of Undetermined Source (RESPECT ESUS)
Brief Summary: This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is not mandatory. All Adverse Events (AEs), Serious Adverse Events (SAEs), outcome events will be recorded. The trial will conclude when the required number of stroke events are positively adjudicated which is estimated to take 3 years (including 2.5 years of enrollment).


Options:
A: Arm Label: Apixaban; Type: EXPERIMENTAL; Interventions: Drug: Apixaban | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Apixaban; Assigned to Arm(s): Apixaban | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin
B: Arm Label: Low dose Argatroban + rt-PA (alteplase); Type: EXPERIMENTAL; Interventions: Drug: Low Dose Argatroban, Drug: rt-PA (alteplase) | Arm Label: High dose Argatroban + rt-PA (alteplase); Type: EXPERIMENTAL; Interventions: Drug: High Dose Argatroban, Drug: rt-PA (alteplase) | Arm Label: rt-PA (alteplase); Type: ACTIVE_COMPARATOR; Interventions: Drug: rt-PA (alteplase) | Intervention Type: DRUG; Name: Low Dose Argatroban; Assigned to Arm(s): Low dose Argatroban + rt-PA (alteplase) | Intervention Type: DRUG; Name: High Dose Argatroban; Assigned to Arm(s): High dose Argatroban + rt-PA (alteplase) | Intervention Type: DRUG; Name: rt-PA (alteplase); Assigned to Arm(s): High dose Argatroban + rt-PA (alteplase), Low dose Argatroban + rt-PA (alteplase), rt-PA (alteplase)
C: Arm Label: dabigatran etexilate 110 or 150 mg; Type: EXPERIMENTAL; Interventions: Drug: optional ASA as comedication, Drug: placebo to ASA, Drug: dabigatran etexilate | Arm Label: ASA 100 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: placebo to optional ASA as comedication, Drug: placebo to dabigatran etexilate, Drug: ASA 100 mg | Intervention Type: DRUG; Name: optional ASA as comedication; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg | Intervention Type: DRUG; Name: placebo to ASA; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg | Intervention Type: DRUG; Name: placebo to optional ASA as comedication; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: placebo to dabigatran etexilate; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: ASA 100 mg; Assigned to Arm(s): ASA 100 mg | Intervention Type: DRUG; Name: dabigatran etexilate; Assigned to Arm(s): dabigatran etexilate 110 or 150 mg
D: Arm Label: Clopidogrel-aspirin; Type: EXPERIMENTAL; Interventions: Drug: Clopidogrel-aspirin | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Warfarin | Intervention Type: DRUG; Name: Warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Clopidogrel-aspirin; Assigned to Arm(s): Clopidogrel-aspirin

Answer: C